Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma: Final appraisal document

DRAFT guidance recommends carfilzomib plus lenalidomide and dexamethasone as an option for treating multiple myeloma in adults, only if they have had only 1 previous therapy, which included bortezomib, and company provides it according to the commercial arrangement.

Source:

National Institute for Health and Care Excellence